Oral microparticulate vaccine for melanoma using M-cell targeting

References

• Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. (2002). Targeting to macrophages: Role of physicochemical properties of particulate carriers–liposomes and microspheres–on the phagocytosis by macrophages. J Control Release, 79, 29–40.
   PubMed Web of Science ®Google Scholar
• Akande J, Yeboah KG, Addo RT, Siddiq A, Oettinger CW, D’Souza MJ. (2010). Targeted delivery of antigens to the gut associated lymphoid tissues. J Microencapsul, 27, 325–336.
   PubMed Web of Science ®Google Scholar
• Balashova E, Lokhov P. (2010). Cellular cancer vaccines: An update on the development of vaccines generated from cell surface antigens. Journal of Cancer, 1, 230–241.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. (1998). Dendritic cells and the control of immunity. Nature, 392, 245–252.
   PubMed Web of Science ®Google Scholar
• Benencia F, Courrèges MC, Conejo-García JR, Mohammed-Hadley A, Coukos G. (2006). Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. Cancer Biol Ther, 5, 867–874.
   PubMed Web of Science ®Google Scholar
• Bramwell VW, Perrie Y. (2005). Particulate delivery systems for vaccines. Crit Rev Ther Drug Carrier Syst, 22, 151–214.
   PubMed Web of Science ®Google Scholar
• Brown WR. (1996). Enteric immunization: Promises and challenges. Dig Dis, 14, 192–200.
   PubMed Web of Science ®Google Scholar
• Bumgarner GW. (2002). Evaluation of the microparticle as an adjuvant or coadjuvant in a tumor vaccine. Ph.D Thesis, Mercer University, US.
   Google Scholar
• Bye WA, Allan CH, Trier JS. (1984). Structure, distribution, and origin of M cells in Peyer’s patches of mouse ileum. Gastroenterology, 86, 789–801.
   PubMed Web of Science ®Google Scholar
• Chen H, Torchilin V, Langer R. (1996). Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm Res, 13, 1378–1383.
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Vaughan MM, Gore ME. (1999). New approaches to the systemic treatment of melanoma. Cancer Treat Rev, 25, 259–270.
   PubMed Web of Science ®Google Scholar
• Ciftci K, Trovitch P. (2003). Current approaches in the treatment of melanoma-II: Immune-and gene therapy. Turk J Canc, 33, 127–136.
   Google Scholar
• Clark MA, Blair H, Liang L, Brey RN, Brayden D, Hirst BH. (2001). Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine, 20, 208–217.
   PubMed Web of Science ®Google Scholar
• Clark MA, Jepson MA, Hirst BH. (2001). Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev, 50, 81–106.
   PubMed Web of Science ®Google Scholar
• Copier J, Dalgleish A. (2006). Overview of tumor cell-based vaccines. Int Rev Immunol, 25, 297–319.
   PubMed Web of Science ®Google Scholar
• Crennell S, Garman E, Laver G, Vimr E, Taylor G. (1994). Crystal structure of Vibrio cholerae neuraminidase reveals dual lectin-like domains in addition to the catalytic domain. Structure, 2, 535–544.
   PubMed Web of Science ®Google Scholar
• D’Souza MJ, DeSouza PJ. (1995). Site specific microencapsulated drug targeting strategies to the liver and the gastrointestinal tract. Adv Drug Delivery Reviews, 17, 247–254.
   Web of Science ®Google Scholar
• D’Souza MJ, Pourfarzib R. (1999). Improved efficacy of a microencapsulated macrophage colony stimulating factor and methotrexate in melanoma. Drug Dev Ind Pharm, 25, 583–590.
   PubMed Web of Science ®Google Scholar
• Doyle K, Beer S, Vorhies P.(2010). The ongoing hopes and challenges of cancer. Oncology business review, 1, 26–30.
   Google Scholar
• Franziska RW, Bohle B, Scholl I, Untersmayr E, Gaborf F, Jensen-Jarolim E. (2005). Targeting antigens to muirine and human M cells with Aleuria aurantia lectin-functionalized microparticles. Immunol Letters, 100, 182–188.
   PubMed Web of Science ®Google Scholar
• Foged C, Brodin B, Frokjaer S, Sundblad A. (2005). Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm, 298, 315–322.
   PubMed Web of Science ®Google Scholar
• Gayakwad SG, Bejugam NK, Akhavein N, Uddin NA, Oettinger CE, D’Souza MJ. (2009). Formulation and in vitro characterization of spray-dried antisense oligonucleotide to NF-κB encapsulated albumin microspheres. J Microencapsul, 26, 692–700.
   PubMed Web of Science ®Google Scholar
• Genta I, Perugini P, Pavanetto F, Modena T, Conti B, Muzzarelli RA. (1999). Microparticulate drug delivery systems. EXS, 87, 305–313.
   PubMedGoogle Scholar
• Goldsby RA, Kindt TJ, Osborne BA. (2000). Kuby Immunology. WH. Freeman and Company Publisher and Distributor: NY.
   Google Scholar
• Malik B, Goyal AK, Mangal S, Zakir F, Vyas SP. (2010). Implication of gut immunology in the design of oral vaccines. Curr Mol Med, 10, 47–70.
   PubMed Web of Science ®Google Scholar
• Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. (2009). Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine, 4, 99–105.
   PubMed Web of Science ®Google Scholar
• Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R. (1992). Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg, 216, 463–482.
   PubMed Web of Science ®Google Scholar
• Morton DL, Barth A. (1996). Vaccine therapy for malignant melanoma. CA Cancer J Clin, 46, 225–244.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT. (1998). Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev, 34, 305–320.
   PubMed Web of Science ®Google Scholar
• Peter I, Mezzacasa A, LeDonne P, Dummer R, Hemmi S. (2001). Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3. Melanoma Res, 11, 21–30.
   PubMed Web of Science ®Google Scholar
• Slaper H, Velders GJ, Daniel JS, de Gruijl FR, van der Leun JC. (1996). Estimates of ozone depletion and skin cancer incidence to examine the Vienna Convention achievements. Nature, 384, 256–258.
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. (1988). Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials, 9, 356–362.
   PubMed Web of Science ®Google Scholar
• Uddin AN, Bejugam NK, Gayakwad SG, Akther P, D’Souza MJ. (2009). Oral delivery of gastro-resistant microencapsulated typhoid vaccine. J Drug Target, 17, 553–560.
   PubMed Web of Science ®Google Scholar
• Ward S, Casey D, Labarthe MC, Whelan M, Dalgleish A, Pandha H, Todryk S. (2002). Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother, 51, 351–357.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang X, Csencsits KL, Haddad A, Walters N, Pascual DW. (2001). M cell-targeted DNA vaccination. Proc Natl Acad Sci USA, 98, 9318–9323.
   PubMed Web of Science ®Google Scholar
• Weinstein DL, O’Neill BL, Hone DM, Metcalf ES. (1998). Differential early interactions between Salmonella enterica serovar Typhi and two other pathogenic Salmonella serovars with intestinal epithelial cells. Infect Immun, 66, 2310–2318.
   PubMed Web of Science ®Google Scholar
• Wolf JL, Rubin DH, Finberg R, Kauffman RS, Sharpe AH, Trier JS, Fields BN. (1981). Intestinal M cells: A pathway for entry of reovirus into the host. Science, 212, 471–472.
   PubMed Web of Science ®Google Scholar
• Lai YH, D’Souza MJ. (2007). Formulation and evaluation of an oral melanoma vaccine. J Microencapsul, 24, 235–252.
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kündig T, Hengartner H. (1997). Antigen localisation regulates immune responses in a dose- and time-dependent fashion: A geographical view of immune reactivity. Immunol Rev, 156, 199–209.
   PubMed Web of Science ®Google Scholar